Asset profile
pemvidutide
Peptide
Evidence outlook · registrational
MASH / NASH: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2028-12.
IMPACT (NCT05989711): This randomised, quadruple-blind, placebo-controlled trial in 212 patients with MASH used resolution of steatohepatitis without worsening fibrosis as its primary endpoint, a biopsy-based clinical measure.
Also in development:MASH · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
34 competitors in this universe: 2 direct rivals (same mechanism and indication), 4 same-class, 28 same-indication; 3 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pemvidutide: this drug | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| OPK-88006 | Phase 1/2 | — | GLP-1/glucagon receptor (dual) | ||
| Mazdutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| AZD9550 | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| PB-718 | Phase 1/2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| DA-1726 | Phase 1 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor |
…and 19 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.